Search clinical trials for: nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab

Total 402 results

Yang Jianjun, PhD

Recruiting

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Advanced Gastric Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer

Gastric Cancer
Jianjun Yang
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Shanghai East Hospital

Not yet recruiting

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Biliary Tract Carcinoma

Biliary Tract Cancer

China
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Completed

Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Fudan University

Unknown

Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Chang Gung Memorial Hospital

Recruiting

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma (GAS)

Metastatic Pancreatic Adenocarcinoma

Taiwan
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
Women's Hospital School Of Medicine Zhejiang University
Sun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaborators

Recruiting

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Epithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IV

China
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Liza Villaruz, MD

Completed

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Pancreatic Cancer Action Network

Active, not recruiting

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
Yang Jianjun, PhD

Recruiting

Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
Yang Jianjun, PhD

Not yet recruiting

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Chinese PLA General Hospital

Recruiting

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | PDAC - Pancreatic Ductal Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

Pancreatic Neoplasms

China
Peking Union Medical College Hospital

Unknown

Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Peking Union Medical College Hospital

Unknown

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Cancer

China
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
AIPING ZHOU

Completed

The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma

Biliary Tract Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Hebei Medical University

Not yet recruiting

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
SCRI Development Innovations, LLC
Celgene

Completed

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Gastroesophageal Cancer

United States
West China Hospital

Not yet recruiting

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Gastric Cancer
Ruijin Hospital

Recruiting

Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

Stage IIIC Gastric Cancer

China
Fundacion Oncosur

Completed

Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer (neurabrax)

Breast Cancer

Spain
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal-junction Cancer

China
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
Zhejiang Cancer Hospital

Recruiting

Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

Gastric Cancer | Peritoneal Metastases | Ascites, Malignant

China
Fourth Affiliated Hospital of Guangxi Medical University

Recruiting

Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer

Uterine Cervical Neoplasms | Adjuvant Chemotherapy | Chemoradiotherapy

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
Affiliated Hospital of Qinghai University

Unknown

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Gastric Cancer

China
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (BEECH)

Advanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast Cancer

Canada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Unknown

Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

Cancer of Pancreas

China
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
AIPING ZHOU

Completed

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Eli Lilly and Company

Completed

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, Taiwan, Japan
National Health Research Institutes, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Completed

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers (SOLAR)

Gastric Cancer in Situ | Pancreatic Cancers | Biliary Cancers

Taiwan
Assiut University

Completed

Phaco-Trabeculotomy Vs Phaco-Trabeculectomy (PDT vs PT)

Glaucoma | Glaucoma, Angle-Closure | Ophthalmopathy

Egypt
National Health Research Institutes, Taiwan
China Medical University Hospital; Kaohsiung Medical University Chung-Ho Memorial... and other collaborators

Recruiting

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Phase II, Open-label, Parallel 2-arm, Multi-center

Taiwan
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Adenocarcinoma | NSCLC | Squamous Cell Carcinoma

3

Subscribe